All In Biotech

NDA 011366 · Xeris

Keveyis

Dichlorphenamide · Oral · Carbonic Anhydrase Inhibitor

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Nov 22, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1958

Jul 22, 1958

Approved uses

3

Original approval plus efficacy supplements

Registered trials

2

2 Phase 3, 0 recruiting

FAERS reports

1,646

461 serious, 13 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 4, 2026.

KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. KEVEYIS is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants ( 1 )

Mechanism: Dichlorphenamide is a carbonic anhydrase inhibitor. However, the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with primary periodic paralysis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 22, 2019 Supplement 33 · Efficacy OrphanLetterLabel
  • Aug 7, 2015 Supplement 30 · Efficacy · priority review OrphanLetterLabel
  • Jul 22, 1958 Original approval · Type 1 - New Molecular Entity
2 products under this application
  • KEVEYIS · DICHLORPHENAMIDE 50MG · TABLET, ORAL · Prescription · TE AB
  • DARANIDE · DICHLORPHENAMIDE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Dichlorphenamide" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • paraesthesia304
  • fatigue231
  • disease recurrence173
  • muscular weakness165
  • feeling abnormal162
  • wrong technique in product usage process151
  • asthenia145
  • confusional state129
  • dizziness119
  • nausea117
  • headache102
  • blood potassium decreased97

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20159
201637
2017158
2018313
2019261
2020295
2021348
202233
202338
202463
202555
202635

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Keveyis (Dichlorphenamide)

2024 spending

$23.5M

Beneficiaries

111

838 claims

Per beneficiary

$211,771

$374.18 per unit

View as table
YearSpending
2020$0
2021$0
2022$354,402
2023$20,667,743
2024$23,506,537

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11 on PubMed

Sponsor: Xeris · Also marketed as Daranide

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.